132 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
3 Nov 21
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
4:11pm
Phase 2 Phase 3 Status LUM-201 (Ibutamoren) In PGHD Phase 2 Ongoing Phase 2 trial with 6-month data readout expected in second half of 2023 Long-term extension … Proposed long-term extension study for OraGrowtH Trials PK/PD trial Pharmacokinetic/Pharmacodynamic (PK/PD) trial open and recruiting patients
8-K
EX-99.1
LUMO
Lumos Pharma Inc
9 Mar 21
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
4:26pm
alternate sites to conduct the trial in the event that the original site is unable to proceed in a timely manner.
OraGrowtH211 Trial, a Long-Term Extension … Study, is Announced – Lumos Pharma announced the OraGrowtH211 Trial, an extension study to determine the long-term safety, PK/PD markers and growth
8-K
EX-99.2
LUMO
Lumos Pharma Inc
5 Aug 21
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:27pm
half of 2023 Long-term extension Long-term extension study for OraGrowtH210, OraGrowtH212, and future OraGrowtH Trials PK/PD trial Pharmacokinetic … Cash runway through primary outcome data for OraGrowtH210 & OraGrowtH212 Trials High quality, long-term investors
8-K
EX-99.1
LUMO
Lumos Pharma Inc
21 Jul 21
Lumos Pharma Announces Clinical Updates
8:33am
of the OraGrowtH211 long-term extension study. The FDA has placed our planned long-term extension study on partial clinical hold until additional … efficacy data from the OraGrowtH210 Trial are available to be reviewed. We are currently reviewing the timing of the start of the long-term extension study
8-K
EX-99.1
LUMO
Lumos Pharma Inc
5 Aug 21
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:27pm
to capture additional data for future regulatory filings and to meet FDA requirements to initiate our proposed 3-year long-term extension study … liabilities:
Accounts payable
Accrued expenses
Current portion of lease liability
Total current liabilities
Long-term liabilities:
Royalty obligation
8-K
EX-99.1
b8c 0q91v
3 May 18
NewLink Genetics Reports First Quarter 2018 Financial Results
4:33pm
8-K
EX-99.2
j6h0gj tc4nof
10 Aug 22
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
12:00am
SC TO-I/A
EX-99
l0dj fh5f
22 Jul 19
Issuer tender offer statement (amended)
12:00am
8-K
EX-99.2
183op8m9cbnebv16wkki
9 Mar 21
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
4:26pm
8-K
EX-99.1
irm4cehigzxte7wu4
26 Feb 15
NewLink Genetics Corporation Provides Operational Update and Reports Fourth Quarter and Year End 2014 Financial Results
12:00am
8-K
EX-99.1
s352e reqhahzcyus
31 Oct 12
NewLink Genetics Corporation Reports Third Quarter 2012 Financial Results
12:00am
8-K/A
EX-99.1
8jrsyr8qs
2 Nov 18
NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
12:03pm
8-K/A
EX-99.3
syfd d8fs0
1 Jun 20
Other Events
12:00am
8-K
EX-99.1
6w2uqlx
30 Jul 19
NewLink Genetics Provides Corporate Update and Reports Second Quarter 2019 Financial Results
8:36am
8-K
EX-99.1
bslff ih5tq
6 May 13
NewLink Genetics Corporation Reports First Quarter 2013 Financial Results
12:00am
SC TO-I
EX-99
1hpmq4f5vhs2d3qv00
20 Jun 19
Issuer tender offer statement
4:25pm
8-K
EX-1
duv9i199x0dv9pl12hk0
29 Mar 12
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
rxqv 29yx8ipyr096pm7
6 Nov 19
NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
8:34am
8-K
EX-99.1
2am026rdo1ecp
5 Aug 14
NewLink Genetics Corporation Reports Second Quarter 2014 Financial Results
12:00am
8-K
EX-99.2
i3yi3fgc6cyqww
10 Mar 22
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
4:20pm